Hyperthyroidism and Graves disease — branching viva

Opening framework

My framework has three layers. First, the recognition — a suppressed TSH with a raised free T4 confirms thyrotoxicosis, and a positive TSH-receptor antibody confirms Graves disease and makes the radioiodine scan unnecessary in most children. Second, the mechanism — a stimulating antibody switches on the TSH receptor without any pituitary brake, driving hormone synthesis and the beta-adrenergic storm that defines the clinical picture. Third, the management — a beta-blocker bridges the symptoms while carbimazole or methimazole controls the gland, and propylthiouracil is held for thyroid storm and first-trimester pregnancy because of fulminant hepatotoxicity in children. [1]

The adolescent with Graves disease

The diagnosis is Graves disease. A stimulating TSH-receptor antibody binds and constitutively activates the TSH receptor on the thyroid follicular cell, bypassing the pituitary negative-feedback loop and driving unregulated T4 and T3 synthesis, follicular hypertrophy and increased vascularity — hence the diffuse goitre with a bruit. The hormone excess up-regulates beta-adrenergic receptors, producing the tachycardia, bounding pulse, wide pulse pressure, tremor, anxiety and heat intolerance, and accelerates metabolism, producing weight loss with increased appetite. The eye signs — proptosis, lid retraction and lid lag — are antibody-driven, because the antibody acts on retro-orbital fibroblasts and adipocytes to cause glycosaminoglycan accumulation and orbital swelling, and they are the fingerprint that separates Graves from every other cause of thyrotoxicosis. [1] [3]

First-line management and the propylthiouracil caveat

Carbimazole or methimazole is first-line, at a paediatric starting dose of roughly 0.25 to 1 mg/kg per day methimazole equivalent, titrated to the free T4 every four to six weeks. It is dosed once daily, is more effective than propylthiouracil, and carries a lower risk of liver failure, which is why it displaced propylthiouracil in children after the hepatotoxicity signal. A beta-blocker (propranolol roughly 0.5 to 2 mg/kg per day in divided doses) bridges the beta-adrenergic symptoms within hours. The titration regimen — start at a standard dose and taper to the lowest euthyroid dose — is preferred in children over the block-and-replace regimen. Propylthiouracil is reserved for thyroid storm (because it additionally blocks the peripheral conversion of T4 to T3) and first-trimester pregnancy (because of the lower teratogenic risk than methimazole in early organogenesis), and otherwise avoided because of the risk of fulminant liver failure. [1] [6] [9]

Branch: the infant of a mother with burnt-out Graves disease

For the two-week-old infant — tachycardic, irritable, failing to thrive, with a goitre and a mother rendered hypothyroid by radioactive iodine — the diagnosis is neonatal thyrotoxicosis from transplacental antibody. The key teaching point is that the risk travels with the antibody, not the mother's thyroid status: radioactive iodine ablated her gland but left her antibody-positive, and that antibody still crossed the placenta to drive the fetal and neonatal thyroid. The condition is transient, resolving as the maternal antibody clears over three to six months, and is managed with methimazole and a beta-blocker with the dose tapered as the antibody wanes. The surveillance rule is absolute: every infant of a mother with a history of Graves disease — treated or untreated, active or burnt-out — has cord or neonatal thyroid function and a TSH-receptor antibody checked and is monitored through the first months, because the disease can be fatal if missed yet self-resolves if found. [11]

Closing: the thyrotoxic adolescent who is febrile and confused

The closing branch — an adolescent who has stopped her tablets and presents febrile and confused — is thyroid storm, the decompensated extreme of thyrotoxicosis and a clinical diagnosis treated before the laboratory confirms it. The four-pronged regimen is given together: propylthiouracil to block synthesis and T4-to-T3 conversion, iodine (given at least an hour after the thionamide) to block hormone release, a beta-blocker with corticosteroids to block the peripheral effects, and supportive PICU care with cooling, fluids and treatment of the precipitant — here, non-adherence. The longer lesson is the long game: roughly half to two-thirds of children relapse after a standard two-to-three-year course, predicted by a large goitre, a high antibody titre, severe disease and young age, and the response is a shared decision between prolonged medical therapy and definitive radioactive iodine or surgery, built around a structured adolescent-to-adult transition that prevents exactly this kind of disengagement. [1] [3] [5] [6]